Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris Sells 5,698 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris sold 5,698 shares of the stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $24.31, for a total value of $138,518.38. Following the completion of the sale, the chief executive officer now owns 1,496,729 shares of the company’s stock, valued at $36,385,481.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tyra Biosciences Price Performance

Shares of TYRA stock traded up $0.37 on Friday, reaching $24.36. 249,447 shares of the company were exchanged, compared to its average volume of 147,808. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -14.50 and a beta of 1.01. The company has a 50-day moving average of $21.20 and a 200-day moving average of $18.70. Tyra Biosciences, Inc. has a one year low of $10.38 and a one year high of $25.14.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. As a group, sell-side analysts predict that Tyra Biosciences, Inc. will post -1.53 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $23.00 price objective on shares of Tyra Biosciences in a report on Wednesday, July 3rd. Piper Sandler started coverage on shares of Tyra Biosciences in a research report on Thursday, August 15th. They set an “overweight” rating and a $33.00 price target on the stock. Oppenheimer upped their price target on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, Wedbush reaffirmed an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research report on Thursday, August 8th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $26.40.

Hedge Funds Weigh In On Tyra Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in TYRA. Rhumbline Advisers increased its stake in Tyra Biosciences by 12.3% in the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after buying an additional 2,574 shares during the last quarter. Wellington Management Group LLP increased its stake in Tyra Biosciences by 8.8% in the 4th quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock valued at $1,419,000 after buying an additional 8,324 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Tyra Biosciences by 32.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after buying an additional 14,352 shares during the last quarter. HighVista Strategies LLC purchased a new stake in Tyra Biosciences in the 2nd quarter valued at about $257,000. Finally, Victory Capital Management Inc. increased its stake in Tyra Biosciences by 53.4% in the 4th quarter. Victory Capital Management Inc. now owns 50,220 shares of the company’s stock valued at $696,000 after buying an additional 17,490 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.